Raul R. Calvo

2.0k total citations
22 papers, 1.0k citations indexed

About

Raul R. Calvo is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Raul R. Calvo has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Hematology. Recurrent topics in Raul R. Calvo's work include Platelet Disorders and Treatments (7 papers), Cancer-related Molecular Pathways (6 papers) and Cell Adhesion Molecules Research (5 papers). Raul R. Calvo is often cited by papers focused on Platelet Disorders and Treatments (7 papers), Cancer-related Molecular Pathways (6 papers) and Cell Adhesion Molecules Research (5 papers). Raul R. Calvo collaborates with scholars based in United States and Spain. Raul R. Calvo's co-authors include Tianbao Lu, Maxwell D. Cummings, Fadia E. Ali, Daniel J. Parks, Karen L. Milkiewicz, Louis V. LaFrance, James M. Samanen, Jennifer Lattanze, Bruce Grasberger and Todd T. Romoff and has published in prestigious journals such as Journal of the American Chemical Society, Advanced Drug Delivery Reviews and Journal of Medicinal Chemistry.

In The Last Decade

Raul R. Calvo

22 papers receiving 962 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raul R. Calvo United States 16 615 309 295 241 143 22 1.0k
Kenneth M. Comess United States 16 756 1.2× 279 0.9× 189 0.6× 327 1.4× 70 0.5× 17 1.2k
Chu‐Biao Xue United States 22 577 0.9× 197 0.6× 320 1.1× 94 0.4× 76 0.5× 52 1.0k
Marcel Mueller Switzerland 8 408 0.7× 189 0.6× 209 0.7× 77 0.3× 105 0.7× 9 800
Wen‐Cherng Lee United States 15 627 1.0× 224 0.7× 132 0.4× 214 0.9× 32 0.2× 21 1000
Benjamin R. Bowen United States 18 875 1.4× 112 0.4× 239 0.8× 149 0.6× 32 0.2× 25 1.2k
K. Ulrich Wendt Germany 18 662 1.1× 246 0.8× 167 0.6× 61 0.3× 98 0.7× 29 1.0k
John Porter United Kingdom 19 548 0.9× 213 0.7× 241 0.8× 80 0.3× 43 0.3× 38 1.1k
Guixian Jin United States 15 714 1.2× 264 0.9× 108 0.4× 73 0.3× 38 0.3× 21 1.1k
Terence A. Kelly United States 16 949 1.5× 193 0.6× 464 1.6× 140 0.6× 33 0.2× 26 1.5k
David Y. Jackson United States 16 835 1.4× 204 0.7× 455 1.5× 179 0.7× 28 0.2× 21 1.2k

Countries citing papers authored by Raul R. Calvo

Since Specialization
Citations

This map shows the geographic impact of Raul R. Calvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raul R. Calvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raul R. Calvo more than expected).

Fields of papers citing papers by Raul R. Calvo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raul R. Calvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raul R. Calvo. The network helps show where Raul R. Calvo may publish in the future.

Co-authorship network of co-authors of Raul R. Calvo

This figure shows the co-authorship network connecting the top 25 collaborators of Raul R. Calvo. A scholar is included among the top collaborators of Raul R. Calvo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raul R. Calvo. Raul R. Calvo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Parsons, William H., Raul R. Calvo, Wing S. Cheung, et al.. (2015). Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). Journal of Medicinal Chemistry. 58(9). 3859–3874. 19 indexed citations
2.
Calvo, Raul R., Sanath K. Meegalla, Daniel J. Parks, et al.. (2012). Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia. Bioorganic & Medicinal Chemistry Letters. 22(5). 1903–1907. 31 indexed citations
3.
Cheung, Wing S., Raul R. Calvo, Brett A. Tounge, et al.. (2008). Discovery of piperidine carboxamide TRPV1 antagonists. Bioorganic & Medicinal Chemistry Letters. 18(16). 4569–4572. 15 indexed citations
4.
Cummings, Maxwell D., Carsten J. Schubert, Daniel J. Parks, et al.. (2006). Substituted 1,4‐Benzodiazepine‐2,5‐diones as α‐Helix Mimetic Antagonists of the HDM2‐p53 Protein–Protein Interaction. Chemical Biology & Drug Design. 67(3). 201–205. 37 indexed citations
5.
Leonard, Kristi, Juan Marugán, Pierre Raboisson, et al.. (2006). Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorganic & Medicinal Chemistry Letters. 16(13). 3463–3468. 49 indexed citations
6.
Parks, Daniel J., Louis V. LaFrance, Raul R. Calvo, et al.. (2006). Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein–protein interaction through structure-based drug design. Bioorganic & Medicinal Chemistry Letters. 16(12). 3310–3314. 57 indexed citations
7.
Marugán, Juan, Kristi Leonard, Pierre Raboisson, et al.. (2006). Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists. Bioorganic & Medicinal Chemistry Letters. 16(12). 3115–3120. 23 indexed citations
8.
Koblish, Holly K., Shuyuan Zhao, Carol F. Franks, et al.. (2006). Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Molecular Cancer Therapeutics. 5(1). 160–169. 131 indexed citations
9.
Parks, Daniel J., Louis V. LaFrance, Raul R. Calvo, et al.. (2004). 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2–p53 interaction: discovery and SAR. Bioorganic & Medicinal Chemistry Letters. 15(3). 765–770. 130 indexed citations
10.
Keenan, Richard M., William H. Miller, M. Amparo Lago, et al.. (1998). Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (αvβ3) antagonists. Bioorganic & Medicinal Chemistry Letters. 8(22). 3165–3170. 18 indexed citations
11.
Samanen, James M., Chao‐Pin Lee, Philip L. Smith, et al.. (1997). The use of rabbit intestinal permeability as an in vitro assay in the search for orally active GPIIb/IIIa antagonists. Advanced Drug Delivery Reviews. 23(1-3). 133–142. 1 indexed citations
12.
Carlos, Rita Q., et al.. (1996). Interaction between propofol and sulfisoxazole in mice an in vivo and in vitro study.. PubMed. 93(1). 89–100. 1 indexed citations
13.
Miller, William H., Thomas W. Ku, Fadia E. Ali, et al.. (1995). Enantiospecific synthesis of SB 214857, a potent, orally active, nonpeptide fibrinogen receptor antagonist. Tetrahedron Letters. 36(52). 9433–9436. 39 indexed citations
14.
Nichols, Andrew J., Richard E. Valocik, Barbara L. Storer, et al.. (1994). The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. Thrombosis Research. 75(2). 143–156. 5 indexed citations
15.
Ali, Fadia E., Donald B. Bennett, Raul R. Calvo, et al.. (1994). Conformationally Constrained Peptides and Semipeptides Derived from RGD as Potent Inhibitors of the Platelet Fibrinogen Receptor and Platelet Aggregation. Journal of Medicinal Chemistry. 37(6). 769–780. 35 indexed citations
16.
Ku, Thomas W., Fadia E. Ali, John W. Bean, et al.. (1993). Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. Journal of the American Chemical Society. 115(19). 8861–8862. 67 indexed citations
17.
Peishoff, Catherine E., Fadia E. Ali, John W. Bean, et al.. (1992). Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides. Journal of Medicinal Chemistry. 35(21). 3962–3969. 78 indexed citations
18.
Samanen, James M., Todd T. Romoff, Raul R. Calvo, et al.. (1991). Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. Journal of Medicinal Chemistry. 34(10). 3114–3125. 156 indexed citations
19.
20.
Nichols, A., Paul F. Koster, Jean A. Smith, et al.. (1990). SK&F 106760, a novel GPIIB/IIIA antagonist: antithrombotic activity and potentiation of streptokinase-mediated thrombolysis. European Journal of Pharmacology. 183(5). 2019–2019. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth M. Comess Breakdown of academic impact, for papers by Chu‐Biao Xue Breakdown of academic impact, for papers by Marcel Mueller Breakdown of academic impact, for papers by Wen‐Cherng Lee Breakdown of academic impact, for papers by Benjamin R. Bowen Breakdown of academic impact, for papers by K. Ulrich Wendt Breakdown of academic impact, for papers by John Porter Breakdown of academic impact, for papers by Guixian Jin Breakdown of academic impact, for papers by Terence A. Kelly Breakdown of academic impact, for papers by David Y. Jackson
Rankless by CCL
2026